Enbrel 'loses out' to Humira in first-line psoriasis battle
This article was originally published in Scrip
Executive Summary
Enbrel (etanercept; Amgen/Pfizer/Stiefel/Takeda) has been replaced by Humira (adalimumab; Abbott/Eisai) as the preferred first-line therapy in moderate to severe psoriasis, according to primary research recently conducted by Datamonitor Healthcare. The research also suggests that Stelara is gaining ground, while the field is being prepared for the advent of biosimilars.